Triptolide derivatives and preparation method and use thereof

Abstract

Tripyolide-nucleic acid aptamer derivatives, a preparation method and use thereof are shown. The structure of the triptolide-nucleic acid aptamer derivatives is as shown by formula I, wherein the definitions of R.sub.1-R.sub.7, G, A, B, M, Z and X are described. The present invention uses a nucleic acid aptamer and triptolide or modified compounds thereof as the starting materials, and introduces a linking group A at the C-14 hydroxyl group, epoxy groups and five-membered ring lactones in triptolide, then connects it to a nucleic acid aptamer B, and obtains the triptolide-nucleic acid aptamer derivatives. The triptolide-nucleic acid aptamer derivatives of the present invention have the characteristics of good targeting, a high anti-cancer activity, low toxicity and side effects, good water solubility and high bioavailability, and the preparation method of the present invention is scientific and reasonable and has a controllable quality and good repeatability, and is thereby suitable for production.

Claims

1. A triptolide derivative, being a compound of the Formula (I): ##STR00034## R.sub.1=H or OH; R.sub.2=H or OH; R.sub.3=H or OH; R.sub.4=H or OH; R.sub.5=H or OH; R.sub.6=H or OH; R.sub.7=H or OH; G is O or NH; A is —CO—, —CO—(CH.sub.2).sub.n—CO—, —CH═CH—CO—, —CH═CH—(CH.sub.2).sub.n—CO—, —CH(OH)-Ph-CO—, CH(OH)-Ph-(CH.sub.2).sub.n—CO—, —CH.sub.2-Ph-(CH.sub.2).sub.n—CO—, —CO—NH—CO—, —CO—NH—(CH.sub.2).sub.n—CO—, —CH.sub.2—CH═CH—CO—, —CH.sub.2—CH═CH—(CH.sub.2).sub.n—CO—, —CO—CH.sub.2—, —CO—O—(CH.sub.2).sub.n—CO—, —SO.sub.2-Ph-CO—, or —SO.sub.2-Ph-(CH.sub.2).sub.n—CO—; wherein 1≦n≦14; (CH.sub.2).sub.n further comprises a substituent selected from straight or branched alkyl, alkenyl, aralkyl, or alkyl aryalkyl, aryl, halogen, group with a heteroatom, heterocycle substituting one or more H in the (CH.sub.2).sub.n, the alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, hexyl or heptyl; the alkenyl is selected from vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, or the E, Z isomers thereof; the aralkyl and the alkyl aralkyl is selected from benzyl, diphenylmethyl, tolyl methyl, triphenylmethyl, cinnamyl, phenethyl, styryl, phenylbutyl and neophenyl; the aryl is selected from phenyl, diphenyl, tolyl, methylbenzyl, 4,2,6-trimethylphenyl, cumenyl, di(tert-butyl) phenyl, anthryl, indenyl, naphthyl, haloaryl, haloaryl alkylphenoxy, tolyloxy, xylyl alkoxy, 2,4,6-tris tolyloxy and cumene oxy, diphenyl, anilino, toluidino, tosyl, allyl benzyl or phenyl, furanyl, pyridyl, 2-pyridyl (pyridin-2-yl), indol-1-yl, chloromethylbenzyl or phenyl, trifluoromethylbenzyl or phenyl, hydroxybenzyl or phenyl, methoxybenzyl or phenyl, ethoxybenzyl or phenyl, ethoxymethoxybenzyl or phenyl, allyloxybenzyl or phenyl, phenoxybenzyl or phenyl, acetoxybenzyl or phenyl, benzoyloxy benzyl or phenyl, methylthiobenzyl or phenyl, phenylthio benzyl or phenyl, tolylthio benzyl or phenyl, methylaminobenzyl or phenyl, dimethylaminobenzyl or phenyl, ethylaminobenzyl or phenyl, diethylaminobenzyl or phenyl, acetamidobenzyl or phenyl, carboxybenzyl or phenyl, methoxycarbonyl benzyl or phenyl, ethoxycarbonyl benzyl or phenyl, phenoxycarbonyl benzyl or phenyl, chlorophenoxycarbonyl benzyl or phenyl, N-cyclohexylcarbamoyloxy benzyl or phenyl, allyloxycarbonyl benzyl or phenyl, carbamoyl benzyl or phenyl, N-methylcarbamoyl benzyl or phenyl, N,N-dipropyl carbamoyl benzyl or phenyl, N-phenyl-carbamoyl-benzyl or phenyl, nitrobenzyl or phenyl, cyanobenzyl or phenyl, S-benzyl or phenyl, sulfate benzyl or phenyl, phosphonyl benzyl or phenyl, phosphate benzyl or phenyl and morpholino benzyl or phenyl; the halogen comprises fluorine, chlorine, bromine or iodine; the group with the heteroatom is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, isobutylthio, tert-butylthio, methylsulfinyl, ethylsulfinyl, isopropyl sulfinyl, methylsulfonyl, ethylsulfonyl, isopropyl sulfonyl; the heterocycle is selected from pyridine, quinolone, thiophene, furan, oxazole, tetrazole, thiazole, imidazole, pyrazole, or indole; B is an aptamer, and the aptamer is AS1411 or Sgc8c; M is O or OH; Z is O; X is O; wherein A is connected with M, Z or X.

2. The derivative according to claim 1, wherein A is —CO—; —CO—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH═CH—CO—; —CH(OH)-Ph-CO—, —CH(OH)-Ph-CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH.sub.2-Ph-CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CO—NH—CO—, —CO—NH—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH.sub.2—CH═CH—CO—, —CH.sub.2—CH═CH—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO; —CO—CH.sub.2—; —CO—O—CO—, —CO—O—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —SO.sub.2-Ph-CO—, —SO.sub.2-Ph-CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, or —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—.

3. The derivative according to claim 1, wherein the compound has the following structure: ##STR00035## wherein, R.sub.1=H or OH; R.sub.2=H or OH; R.sub.3=H or OH; R.sub.4=H or OH; R.sub.5=H or OH; R.sub.6=H or OH; R.sub.7=H or OH; G is O or NH; M is O; Z is O; X is O; A is selected from —CO—, —CO—(CH.sub.2).sub.n—CO—, —CH═CH—CO—, —CH═CH—(CH.sub.2).sub.n—CO—, —CH(OH)—Ph-CO—,CH(OH)-Ph-(CH.sub.2).sub.n—CO—, —CH.sub.2-Ph-(CH.sub.2).sub.n—CO—, —CO—NH—CO—, —CO—NH—(CH.sub.2).sub.n—CO—, —CH.sub.2—CH═CH—CO—, —CH.sub.2—CH═CH—(CH.sub.2).sub.nCO—, —CO—CH.sub.2—, —CO—O—(CH.sub.2).sub.n—CO—,—SO.sub.2-Ph-CO— or —SO.sub.2-Ph-(CH.sub.2).sub.n—CO—; wherein 1≦n≦14; (CH.sub.2).sub.n further comprises a substituent selected from straight or branched alkyl, alkenyl, aralkyl, alkyl aryalkyl, aryl, halogen, group with a heteroatom, heterocycle substituting one or more H in the (CH.sub.2).sub.n, the alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, hexyl or heptyl; the alkenyl is selected from vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, or the E, Z isomers thereof; the aralkyl and the alkyl aralkyl is selected from benzyl, diphenylmethyl, tolyl methyl, triphenylmethyl, cinnamyl, phenethyl, styryl, phenylbutyl or neophenyl; the aryl is selected from phenyl, diphenyl, tolyl, methylbenzyl, 4,2,6-trimethylphenyl, cumenyl, di(tert-butyl) phenyl, anthryl, indenyl, naphthyl, haloaryl, haloaryl alkylphenoxy, tolyloxy, xylyl alkoxy, 2,4,6-tris tolyloxy and cumene oxy, diphenyl, anilino, toluidino, tosyl, allyl benzyl or phenyl, furanyl, pyridyl, 2-pyridyl (pyridin-2-yl), indol-1-yl, chloromethylbenzyl or phenyl, trifluoromethylbenzyl or phenyl, hydroxybenzyl or phenyl, methoxybenzyl or phenyl, ethoxybenzyl or phenyl, ethoxymethoxybenzyl or phenyl, allyloxybenzyl or phenyl, phenoxybenzyl or phenyl, acetoxybenzyl or phenyl, benzoyloxy benzyl or phenyl, methylthiobenzyl or phenyl, phenylthio benzyl or phenyl, tolylthio benzyl or phenyl, methylaminobenzyl or phenyl, dimethylaminobenzyl or phenyl, ethylaminobenzyl or phenyl, diethylaminobenzyl or phenyl, acetamidobenzyl or phenyl, carboxybenzyl or phenyl, methoxycarbonyl benzyl or phenyl, ethoxycarbonyl benzyl or phenyl, phenoxycarbonyl benzyl or phenyl, chlorophenoxycarbonyl benzyl or phenyl, N-cyclohexylcarbamoyloxy benzyl or phenyl, allyloxycarbonyl benzyl or phenyl, carbamoyl benzyl or phenyl, N-methylcarbamoyl benzyl or phenyl, N,N-dipropyl carbamoyl benzyl or phenyl, N-phenyl-carbamoyl-benzyl or phenyl, nitrobenzyl or phenyl, cyanobenzyl or phenyl, S-benzyl or phenyl, sulfate benzyl or phenyl, phosphonyl benzyl or phenyl, phosphate benzyl or phenyl and morpholino benzyl or phenyl; the halogen comprises fluorine, chlorine, bromine and iodine; the group with the heteroatom is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, isobutylthio, tert-butylthio, methylsulfinyl, ethylsulfinyl, isopropyl sulfinyl, methylsulfonyl, ethylsulfonyl, isopropyl sulfonyl; the heterocycle is selected from pyridine, quinolone, thiophene, furan, oxazole, tetrazole, thiazole, imidazole, pyrazole or indole; B is an aptamer, and the aptamer is AS1411 or Sgc8c.

4. The derivative according to claim 3, wherein A is selected from —CO—; —CO—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH═CH—CO—, —CH═CH—CH.sub.2—CO—, —CH═CH—CH.sub.2—CH.sub.2—CO—, —CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH(OH)-Ph-CO—, —CH(OH)-Ph-CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH.sub.2-Ph-CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CO—NH—CO—, —CO—NH—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH.sub.2—CH═CH—CO—, —CH.sub.2—CH═CH—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO; —CO—CH.sub.2—; —CO—O—CO—, —CO—O—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —SO.sub.2-Ph-CO—, —SO.sub.2-Ph-CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, or —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—.

5. The triptolide derivative according to claim 3, wherein the compound is: TABLE-US-00008 Substituent No. R.sub.1 R.sub.2 R.sub.3 R.sub.4 R.sub.5 R.sub.6 R.sub.7 G M Z X A B (1) H H H H H H H O O O O —CO—CH.sub.2—CH.sub.2—CO— AS1411 (2) H H H H H H H O O O O —CO— AS1411 (3) H H H H H H H O O O O —CH═CH—CO— AS1411 (4) H H H H H H H O O O O —CH(OCH.sub.3)—Ph—CO— AS1411 (5) H H H H H H H O O O O —CH.sub.2—Ph—CH.sub.2—CO— AS1411 (6) H H H H H H H O O O O —CO—NH—CH.sub.2—CO— AS1411 (7) H H H H H H H O O O O —CH.sub.2—CH═CH—CO— AS1411 (8) H H H H H H H O O O O —CO—CH.sub.2— AS1411 (9) H H H H H H H O O O O —CO—O—(CH.sub.2).sub.2—CO— AS1411 (10) H H H H H H H O O O O —CO—CH.sub.2—CO— AS1411 (11) H H H H H H H O O O O —CH═CH—CH.sub.2—CO— AS1411 (12) H H H H H H H O O O O —CH.sub.2—CH═CH—CH.sub.2—CO— AS1411 (13) H H H H H H H O O O O —CO—O—CH.sub.2—CO— AS1411 (14) H H H H H H H O O O O —SO.sub.2—Ph—CH.sub.2—CO— AS1411 (15) H H H H H H H O O O O —CH═CH—CH.sub.2—CH.sub.2—CO— AS1411 (16) H H H H H H H O O O O —CH.sub.2—Ph—CH.sub.2—CH.sub.2—CO— AS1411 (17) H H H H H H H O O O O —CO—NH—CH2—CH.sub.2—CO— AS1411 (18) H H H H H H H O O O O —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CO AS1411 (19) H H H H H H H O O O O —CO—O—CH.sub.2—CH.sub.2—CO AS1411 (20) H H H H H H H O O O O —CO—CH.sub.2—CO— Sgc8c (21) H H H H H H H O O O O —CH═CH—CH.sub.2—CO— Sgc8c (22) H H H H H H H O O O O —CH═CH—CO— Sgc8c (23) H H H H H H H O O O O —CH.sub.2—Ph—CH.sub.2—CO— Sgc8c (24) H H H H H H H O O O O —CO—NH—CH.sub.2—CO— Sgc8c (25) H H H H H H H O O O O —CH.sub.2—CH═CH—CH.sub.2—CO— Sgc8c (26) H H H H H H H O O O O —CO—O—CH.sub.2—CO— Sgc8c (27) H H H H H H H O O O O —SO.sub.2—Ph—CH.sub.2—CO— Sgc8c (28) H H H H H H H O O O O —CO—CH.sub.2—CH.sub.2—CO— Sgc8c (29) H H H H H H H O O O O —CH═CH—CH.sub.2—CH.sub.2—CO— Sgc8c (30) H H H H H H H O O O O CH.sub.2—Ph—CH.sub.2—CH.sub.2—CO— Sgc8c (31) H H H H H H H O O O O —CO—NH—CH.sub.2—CH.sub.2—CO Sgc8c (32) H H H H H H H O O O O —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CO— Sgc8c (33) H H H H H H H O O O O —CO—O—CH.sub.2—CH.sub.2—CO— Sgc8c (34) OH H H H H H H O O O O —CH═CH—CO— AS1411 (35) H OH H H H H H O O O O —CH═CH—CO— AS1411 (36) H H OH H H H H O O O O —CH═CH—CO— AS1411 (37) H H H OH H H H O O O O —CH═CH—CO— AS1411 (38) H H H H OH H H O O O O —CH═CH—CO— AS1411 (39) H H H H H OH H O O O O —CH═CH—CO— AS1411 (40) H H H H H H OH O O O O —CH═CH—CO— AS1411 (41) H H H H H H H NH O O O —CH═CH—CO— AS1411 (42) OH H H H H H H O O O O —CH═CH—CO— Sgc8c (43) H OH H H H H H O O O O —CH═CH—CO— Sgc8c (44) H H OH H H H H O O O O —CH═CH—CO— Sgc8c (45) H H H OH H H H O O O O —CH═CH—CO— Sgc8c (46) H H H H OH H H O O O O —CH═CH—CO— Sgc8c (47) H H H H H OH H O O O O —CH═CH—CO— Sgc8c (48) H H H H H H OH O O O O —CH═CH—CO— Sgc8c (49) H H H H H H H NH O O O —CH═CH—CO— Sgc8c.

6. The derivative according to claim 1, wherein the compound has the following structure: ##STR00036## wherein, R.sub.1=H or OH; R.sub.2=H or OH; R.sub.3=H or OH; R.sub.4=H or OH; R.sub.5=H or OH; R.sub.6=H or OH; R.sub.7=H or OH; G is O or NH; M is OH; Z is O; X is O; A is —SO.sub.2-Ph-CO— or SO.sub.2-Ph-(CH.sub.2).sub.n—CO—; wherein 1≦n≦14; (CH.sub.2).sub.n comprises a substituent selected from straight or branched alkyl, alkenyl, aralkyl, alkyl aryalkyl, aryl, halogen, a group with a heteroatom, heterocycle substituting one or more H in the (CH.sub.2), the alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, hexyl or heptyl; the alkenyl is selected from vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, or the E, Z isomers thereof; the aralkyl and the alkyl aralkyl is selected from benzyl, diphenylmethyl, tolyl methyl, triphenylmethyl, cinnamyl, phenethyl, styryl, phenylbutyl or neophenyl; the aryl is selected from phenyl, diphenyl, tolyl, methylbenzyl, 4,2,6- trimethylphenyl, cumenyl, di(tert-butyl) phenyl, anthryl, indenyl, naphthyl, haloaryl, haloaryl alkylphenoxy, tolyloxy, xylyl alkoxy, 2,4,6-tris tolyloxy and cumene oxy, diphenyl, anilino, toluidino, tosyl, allyl benzyl or phenyl, furanyl, pyridyl, 2-pyridyl (pyridin-2-yl), indol-1-yl, chloromethylbenzyl or phenyl, trifluoromethylbenzyl or phenyl, hydroxybenzyl or phenyl, methoxybenzyl or phenyl, ethoxybenzyl or phenyl, ethoxymethoxybenzyl or phenyl, allyloxybenzyl or phenyl, phenoxybenzyl or phenyl, acetoxybenzyl or phenyl, benzoyloxy benzyl or phenyl, methylthiobenzyl or phenyl, phenylthio benzyl or phenyl, tolylthio benzyl or phenyl, methylaminobenzyl or phenyl, dimethylaminobenzyl or phenyl, ethylaminobenzyl or phenyl, diethylaminobenzyl or phenyl, acetamidobenzyl or phenyl, carboxybenzyl or phenyl, methoxycarbonyl benzyl or phenyl, ethoxycarbonyl benzyl or phenyl, phenoxycarbonyl benzyl or phenyl, chlorophenoxycarbonyl benzyl or phenyl, N-cyclohexylcarbamoyloxy benzyl or phenyl, allyloxycarbonyl benzyl or phenyl, carbamoyl benzyl or phenyl, N-methylcarbamoyl benzyl or phenyl, N,N-dipropyl carbamoyl benzyl or phenyl, N-phenyl-carbamoyl-benzyl or phenyl, nitrobenzyl or phenyl, cyanobenzyl or phenyl, S-benzyl or phenyl, sulfate benzyl or phenyl, phosphonyl benzyl or phenyl, phosphate benzyl or phenyl and morpholino benzyl or phenyl; the halogen comprises fluorine, chlorine, bromine and iodine; the group with the heteroatom is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, isobutylthio, tert-butylthio, methylsulfinyl, ethylsulfinyl, isopropyl sulfinyl, methylsulfonyl, ethylsulfonyl, isopropyl sulfonyl; the heterocycle is selected from pyridine, quinolone, thiophene, furan, oxazole, tetrazole, thiazole, imidazole, pyrazole or indole; B is an aptamer, and the aptamer is AS1411 or Sgc8c.

7. The derivative according to claim 6, wherein A is selected from —SO.sub.2-Ph-CO—, —SO.sub.2-Ph-CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, or —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—.

8. The triptolide derivative according to claim 6, wherein the compound is: TABLE-US-00009 Substituent No. R.sub.1 R.sub.2 R.sub.3 R.sub.4 R.sub.5 R.sub.6 R.sub.7 G M Z X A B (50) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CO— AS1411 (51) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CH.sub.2—CO— AS1411 (52) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CH.sub.2—CH.sub.2—CO— AS1411 (53) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CO— Sgc8c (54) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CH.sub.2—CO— Sgc8c (55) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CH.sub.2—CO— Sgc8c.

9. The derivative according to claim 1, wherein the compound has the following structure: ##STR00037## wherein, R.sub.1=H or OH; R.sub.2=H or OH; R.sub.3=H or OH; R.sub.4=H or OH; R.sub.5=H or OH; R.sub.6=H or OH; R.sub.7=H or OH; G is O or NH; M is OH; Z is O; X is O; A is-CO—, —CO—(CH.sub.2).sub.n—CO—, —CH═CH—CO—, —CH═CH—(CH.sub.2).sub.n—CO—, —CH(OH)-Ph-CO—, —CH(OH)-Ph-(CH.sub.2)—CO—, —CH.sub.2-Ph-(CH.sub.2)—CO—, —CO—NH—CO—, —CO—NH—(CH.sub.2).sub.n—CO—, —CH.sub.2—CH═CH—CO—, —CH.sub.2—CH═CH—(CH.sub.2).sub.n—CO—, —CO—CH.sub.2—; —CO—O—(CH.sub.2).sub.n—CO—, —SO.sub.2-Ph-CO— or SO.sub.2-Ph-(CH.sub.2).sub.n—CO—; wherein 1≦n≦14; (CH.sub.2).sub.n comprises a substituent selected from straight or branched alkyl, alkenyl, aralkyl, alkyl aryalkyl, aryl, halogen, a group with a heteroatom, heterocycle substituting one or more H in the (CH.sub.2).sub.n, the alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, hexyl or heptyl; the alkenyl is selected from vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, or the E, Z isomers thereof; the aralkyl and the alkyl aralkyl is selected from benzyl, diphenylmethyl, tolyl methyl, triphenylmethyl, cinnamyl, phenethyl, styryl, phenylbutyl or neophenyl; the aryl is selected from phenyl, diphenyl, tolyl, methylbenzyl, 4,2,6- trimethylphenyl, cumenyl, di(tert-butyl) phenyl, anthryl, indenyl, naphthyl, haloaryl, haloaryl alkylphenoxy, tolyloxy, xylyl alkoxy, 2,4,6-tris tolyloxy and cumene oxy, diphenyl, anilino, toluidino, tosyl, allyl benzyl or phenyl, furanyl, pyridyl, 2-pyridyl (pyridin-2-yl), indo1-1-yl, chloromethylbenzyl or phenyl, trifluoromethylbenzyl or phenyl, hydroxybenzyl or phenyl, methoxybenzyl or phenyl, ethoxybenzyl or phenyl, ethoxymethoxybenzyl or phenyl, allyloxybenzyl or phenyl, phenoxybenzyl or phenyl, acetoxybenzyl or phenyl, benzoyloxy benzyl or phenyl, methylthiobenzyl or phenyl, phenylthio benzyl or phenyl, tolylthio benzyl or phenyl, methylaminobenzyl or phenyl, dimethylaminobenzyl or phenyl, ethylaminobenzyl or phenyl, diethylaminobenzyl or phenyl, acetamidobenzyl or phenyl, carboxybenzyl or phenyl, methoxycarbonyl benzyl or phenyl, ethoxycarbonyl benzyl or phenyl, phenoxycarbonyl benzyl or phenyl, chlorophenoxycarbonyl benzyl or phenyl, N-cyclohexylcarbamoyloxy benzyl or phenyl, allyloxycarbonyl benzyl or phenyl, carbamoyl benzyl or phenyl, N-methylcarbamoyl benzyl or phenyl, N,N-dipropyl carbamoyl benzyl or phenyl, N-phenyl-carbamoyl-benzyl or phenyl, nitrobenzyl or phenyl, cyanobenzyl or phenyl, S-benzyl or phenyl, sulfate benzyl or phenyl, phosphonyl benzyl or phenyl, phosphate benzyl or phenyl and morpholino benzyl or phenyl; the halogen comprises fluorine, chlorine, bromine or iodine; the group with the heteroatom is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, isobutylthio, tert-butylthio, methylsulfinyl, ethylsulfinyl, isopropyl sulfinyl, methylsulfonyl, ethylsulfonyl, isopropyl sulfonyl; the heterocycle is selected from pyridine, quinolone, thiophene, furan, oxazole, tetrazole, thiazole, imidazole, pyrazole or indole; B is an aptamer, and the aptamer is AS1411 or Sgc8c.

10. The derivative according to claim 9, wherein A is selected from —CO—; —CO—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH═CH—CO—, —CH═CH—CH.sub.2—CO—, —CH═CH—CH.sub.2—CH.sub.2—CO—, —CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH(OH)-Ph-CO—, —CH(OH)-Ph-CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH(OH)-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH.sub.2-Ph-CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CO—NH—CO—, —CO—NH—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—NH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —CH.sub.2—CH═CH—CO—, —CH.sub.2—CH═CH—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CH.sub.2—CH═CH—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO; —CO—CH.sub.2-; —CO—O—CO—, —CO—O—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CH.sub.2—CO—, —CO—O—CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—; —SO.sub.2-Ph-CO—, —SO.sub.2-Ph-CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CO—, —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CO—, or —SO.sub.2-Ph-CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—CO—.

11. The triptolide derivative according to claim 9, wherein the compound is: TABLE-US-00010 Substituent No. R.sub.1 R.sub.2 R.sub.3 R.sub.4 R.sub.5 R.sub.6 R.sub.7 G M Z X A B (56) H H H H H H H O OH O O —CO—CH.sub.2—CO— AS1411 (57) H H H H H H H O OH O O —CH═CH—CH.sub.2—CO— AS1411 (58) H H H H H H H O OH O O —CH═CH—CO— AS1411 (59) H H H H H H H O OH O O —CH.sub.2—Ph—CH.sub.2—CO— AS1411 (60) H H H H H H H O OH O O —CO—NH—CH.sub.2—CO— AS1411 (61) H H H H H H H O OH O O —CH.sub.2—CH═CH—CH.sub.2—CO— AS1411 (62) H H H H H H H O OH O O —CO—O—CH.sub.2—CO— AS1411 (63) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CO— AS1411 (64) H H H H H H H O OH O O —CO—CH.sub.2—CH.sub.2—CO— AS1411 (70) H H H H H H H O OH O O —CO—CH.sub.2—CO— Sgc8c (71) H H H H H H H O OH O O —CH═CH—CH.sub.2—CO— Sgc8c (72) H H H H H H H O OH O O —CH═CH—CO— Sgc8c (73) H H H H H H H O OH O O —CH.sub.2—Ph—CH.sub.2—CO— Sgc8c (74) H H H H H H H O OH O O —CO—NH—CH.sub.2—CO— Sgc8c (75) H H H H H H H O OH O O —CH.sub.2—CH═CH—CH.sub.2—CO— Sgc8c (76) H H H H H H H O OH O O —CO—O—CH.sub.2—CO— Sgc8c (77) H H H H H H H O OH O O —SO.sub.2—Ph—CH.sub.2—CO— Sgc8c (78) H H H H H H H O OH O O —CO—CH.sub.2—CH.sub.2—CO— Sgc8c.

12. A method for treating cancer comprising administering the triptolide derivative according to claim 1 to a subject in need thereof, wherein said cancer is selected from pancreatic cancer, renal cancer, small cell lung cancer, brain cancer, neural cancer, bone cancer, leukemia, lymphoma, intestinal cancer, uterine cancer, breast cancer, liver cancer, prostate cancer, skin cancer, and melanoma.

13. A method for preparing the triptolide derivative according to claim 1, comprising: 1) reacting triptolide or a modified compound thereof with a linking intermediate in an organic solvent at a temperature of from −20° C. to 100° C. and optionally in the presence of a catalyst; 2) reacting an aptamer in an alkaline solution with the product obtained from step 1) in an organic solvent at a temperature of from 0° C. to room temperature.

14. The method according to claim 13, characterized in that, where the aptamer is conjugated to C.sub.18 or C.sub.12, the method further comprises performing a protection reaction for the hydroxyl at C.sub.14, wherein the protection agent is selected from tert-butyldimethylsilyl triflate or benzyl bromide.

15. The method according to claim 13, wherein the organic solvent in step 1) is selected from pyridine, dichloromethane, acetonitrile, N-methyl morpholine, dimethylsulfoxide, triethylamine or N, N-dimethyl pyridine, or combinations thereof.

16. The method according to claim 13, wherein the catalyst in step 1) is silver oxide.

17. The method according to claim 13, wherein the alkaline solution in step 2) is selected from a buffer of sodium carbonate/ sodium bicarbonate, triethylamine or potassium carbonate, or combinations thereof.

18. The method according to claim 13, characterized by, the organic solvent in step 2) is selected from dichloromethane, dimethylsulfoxide, acetonitrile or DMT-MM, or combinations thereof.

19. The method according to claim 13, wherein the linking intermediate in step 2) is selected from: succinic anhydride, phosgene, allyl bromide, propiolic acid, 4-bromomethyl benzoic acid, isocyanate, acyl chloride, chloroformate, benzenesulfonyl chloride or an analog thereof; and wherein said analog is selected from malonic anhydride, glutaric anhydride, heptanoic anhydride, butynoic acid, pentynoic acid, heptynoic acid, ethyl 4-bromo(methoxy)methyl benzoate, ethyl 4-bromomethyl benzoate, methyl isocyanate, methyl 4-bromo-2-butene, 2-bromine acyl chloride, methyl 4- sulfonyl chlorobenzoate, methyl 4-bromo (methoxy) methylbenzoate, methyl 4-bromo (methoxy) methylphenylacetate, methyl 4-bromo (methoxy) methylphenylpropionate, methyl 4-bromo (methoxy) methylphenylbutyrate, methyl 4-bromomethyl benzoate, methyl 4-bromomethyl phenylacetate, methyl 4-bromomethyl phenylpropionate, methyl 4-bromomethyl phenylbutyrate, methyl isocyanate, methyl isocyanatoformate, methyl isocyanatopropionate, methyl isocyanatobutyrate, methyl 4-bromo-2-butenoate, methyl 4-bromo-2-pentenoate, methyl 4-bromo-2-hexenoate, methyl 4-bromo-2-heptenoate, methyl 4-bromo-2-octenoate, 3-(chlorocarbonyl) propionate, benzyl 3-(chlorocarbonyl) acetate, benzyl 3-(chlorocarbonyl) butyrate, benzyl 3-(chlorocarbonyl) pentanoate, benzyl 3-(chlorocarbonyl) hexanoate, benzyl 3-(chlorocarbonyl) heptanoate, 2-bromoacetyl chloride, 2-bromoformyl chloride, 2-bromopropionyl chloride, 2-bromobutyryl chloride, 2-bromopentanoyl chloride, 2-bromohexanoyl chloride, 2-bromoheptanoyl chloride, methyl-4-(chlorosulfonyl)-phenylacetate, methyl-4-(chlorosulfonyl)-phenylpropionate, methyl-4-(chloro sulfonyl)-phenylbutyrate, methyl-4-(chlorosulfonyl)-pentanoate, methyl-4-(chlorosulfonyl)-hexanoate, methyl-4-(chlorosulfonyl)-heptanoate, methyl-4-(chlorosulfonyl)-octanoate, or the ethyl ester, propyl ester, butyl ester, methylphenyl ester, or ethylphenyl ester thereof.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 is the mass spectrum of AS1411 in Embodiment 1;

(2) FIG. 2 is the mass spectrum of Sgc8c in Embodiment 12;

(3) FIG. 3 is the LC-MS spectrum of A-2 in Embodiment 1;

(4) FIG. 4 is the H-NMR spectrum of A-2 in Embodiment 1;

(5) FIG. 5 is the LC-MS spectrum of A-3 (i.e. compound (1)) in Embodiment 1;

(6) FIG. 6 is the HPLC spectrum of A-3 (i.e. compound (1)) in Embodiment 1;

(7) FIG. 7 is the LC-MS spectrum of D-1 in Embodiment 3;

(8) FIG. 8 is the H-NMR spectrum of D-1 in Embodiment 3;

(9) FIG. 9 is the LC-MS spectrum of D-2 in Embodiment 3;

(10) FIG. 10 is the H-NMR spectrum of D-2 in Embodiment 3;

(11) FIG. 11 is the LC-MS spectrum of D-3 (i.e. compound (3)) in Embodiment 3;

(12) FIG. 12 is the HPLC spectrum of D-1 (i.e. compound (3)) in Embodiment 3;

(13) FIG. 13 is the LC-MS spectrum of W-1 in Embodiment 12;

(14) FIG. 14 is the H-NMR spectrum of W-1 in Embodiment 12;

(15) FIG. 15 is the LC-MS spectrum of W-2 in Embodiment 12;

(16) FIG. 16 is the H-NMR spectrum of W-2 in Embodiment 12;

(17) FIG. 17 is the LC-MS spectrum of W-3 (i.e. compound (22)) in Embodiment 12;

(18) FIG. 18 shows the in vitro inhibitory effect of A-3 (i.e. compound (1)) on the growth of BxPC-3, in 24 hr, in Example 1;

(19) FIG. 19 shows the in vitro inhibitory effect of A-3 (i.e. compound (1)) on the growth of BxPC-3, in 48 hr, in Example 1;

(20) FIG. 20 shows the in vitro inhibitory effect of W-3 (i.e. compound (22)) on the growth of CCRF-CEM, in 24 hr, in Example 2;

(21) FIG. 21 shows the in vitro inhibitory effect of W-3 (i.e. compound (22)) on the growth of L-02 in Example 2;

(22) FIG. 22 is the study of the in vivo stability of A-3 (i.e. compound (1)) in Example 3;

(23) FIG. 23 is the study of the stability of A-3 (i.e. compound (1)) in plasma in Example 3;

(24) FIG. 24 is the study of the stability of A-3 (i.e. compound (1)) in heart in Example 3;

(25) FIG. 25 is the study of the stability of A-3 (i.e. compound (1)) in lung in Example 3;

(26) FIG. 26 is the study of the stability of A-3 (i.e. compound (1)) in spleen in Example 3;

(27) FIG. 27 is the study of the stability of A-3 (i.e. compound (1)) in liver in Example 3;

(28) FIG. 28 is the study of the stability of A-3 (i.e. compound (1)) in kidney in Example 3;

(29) FIG. 29 is the study of the stability of A-3 (i.e. compound (1)) in cancer tissue in Example 3.

DETAILED DESCRIPTION

(30) The present invention is further described by the following Embodiments or Examples, but the invention is not limited thereto.

(31) Embodiment 1 Preparation of Compound (1)

(32) ##STR00022##

(33) Experimental Procedures

(34) Synthesis of Compound A-2

(35) Succinic anhydride (125 mg, 1.25 mmol) was added to pyridine solution which contained dissolved TP (150 mg, 0.42 mmol) under room temperature. Under the protection of nitrogen gas, the reaction system was heated to a temperature of 85° C., and the system was maintained at this temperature for 30 hours to facilitate the reaction. When the reaction was complete (the reaction was monitored by TLC), the system was cooled to room temperature, n-hexane was added and the resulting solid was subjected to suction filtration and subsequently the solid product was washed by n-hexane. Finally, the crude product was re-crystallized by using n-haxane/ethyl acetate for purification such that A-2 was obtained.

(36) LC-MS (ESI): [M+H]+: 461; [M+Na]+: 483

(37) 1H NMR (400 MHz, CDCl3) δ=5.09 (s, 1H), 4.68 (s, 2H), 3.83 (d, J=2.8 Hz, 1H), 3.53 (d, J=2.4, 1H), 3.46 (d, J=5.6 Hz, 1H), 2.72 (m, 5H), 2.31 (m, 1H), 2.14 (m, 2H), 1.89 (m, 2H), 1.56 (m, 1H), 1.22 (m, 1H), 1.05 (s, 3H), 0.95 (d, J=7.2 Hz, 3H), 0.83 (d, J=7.2 Hz, 3H).

(38) Synthesis of Compound A-3

(39) 3 mg of AS1411 was dissolved in a buffer of sodium carbonate and sodium bicarbonate with pH=9.0, both A-2 (5.4 μmol, 150 eq.) in DMSO (54 μl) and DMT-MM (5.4 μmol, 200 eq.) in ddH.sub.2O (5.4 μl) were introduced to the buffer at the same time, the reaction system was maintained at room temperature for 12 hours to facilitate the reaction. When the reaction was complete, the crude product was purified by RP HPLC, and target product A-3 was obtained.

(40) MS: calculated 8926 (found 8926.6).

(41) The spectrums of the corresponding starting materials and products in embodiment 1 are shown in FIGS. 1, 3-6.

(42) Embodiment 2 Preparation of Compound (2)

(43) ##STR00023##

(44) Synthesis of Compound B-2

(45) Phosgene (108 mg, 1.1 mmol) was dissolved in dichloromethane, and then TP (360 mg, 1 mmol) in dichloromethane was added dropwise to the solution at a temperature of −20° C. and in the presence of nitrogen gas. After the addition, the reaction was allowed to react at said temperature for 0.5 hr, and then increasing the temperature of the system naturally to reach the room temperature to react for 2 hr. When TLC determined that the reaction was complete, the generated hydrochloric acid gas and unreacted phosgene were removed under reduced pressure. Then, the crude product was directly used in the next step.

(46) Synthesis of Compound B-3

(47) AS1411 (3 mg) was dissolved in dry dichloromethane at 0° C., and triethylamine (2.02 mg, 0.02 mmol) was added to the mixture. Then B-2 (4.22 mg, 0.01 mmol) obtained from the previous step was added dropwise to a reaction flask, subsequently the temperature of the reaction system was naturally increased to the room temperature to react for 4 hours. When TLC or LC-MS determined that the reaction was complete, the resulting compound was then obtained by purification.

(48) MS: calculated 8872 (found 8871.4).

(49) Embodiment 3 Preparation of Compound (3)

(50) ##STR00024##

(51) C-1 (0.91 g, 13 mmol) was dissolved in DMF, sodium bicarbonate (2.18 g, 26 mmol) was added and the mixture was stirred under room temperature for 1 hour. Allyl bromide (2.28 g, 16.9 mmol) was added and the mixture was kept at room temperature for overnight reaction. When TLC determined that the reaction was complete, EA was introduced to the reaction system, and then water was used to perform extraction for several times. Finally the organic phase was dried by anhydrous sodium sulfate, filtered, and subjected to evaporation, and then C-2 crude was obtained.

(52) Synthesis of Compound D-1

(53) TP (50 mg, 139 mol) and C-2 (23 mg, 208 mol) were dissolved in acentonitrile, and then NMM (15 μl, 0.5 eq.) was added to the mixture. This reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After TLC determined that the reaction was complete, the organic solvent was removed under reduced pressure, and the crude product was subjected to a quick silica gel column chromatography so as to obtain the pure product D-1.

(54) LC-MS (ESI): [M+H]+: 471; [M+Na]+: 493

(55) 1H NMR (400 MHz, CDCl.sub.3) δ=7.41 (d, J=12.4 Hz, 1H), 5.91-5.98 (m, 1H), 5.47 (d, J=12.4 Hz, 1H), 5.31 (dd, J=1.2, 17.4 Hz, 1H), 5.22 (dd, J=1.2, 10.4 Hz, 1H), 4.68 (s, 2H), 4.61 (d, J=3.6 Hz, 2H), 3.82 (d, J=3.2 Hz, 1H), 3.69 (s, 1H), 3.60 (d, J=2.8 Hz, 1H), 3.38 (d, J=5.6 Hz, 1H), 2.70 (m, 1H), 2.30 (m, 1H), 2.16-2.22 (m, 1H), 1.92-2.06 (m, 2H), 1.57-1.61 (m, 3H), 1.17-1.25 (m, 3H), 1.07 (s, 3H), 0.97 (d, J=7.2 Hz, 3H), 0.87 (d, J=6.8 Hz, 3H).

(56) Synthesis of Compound D-2

(57) D-1 (15 g, 0.5 eq.) was dissolved in tetrahydrofuran, morpholine (50 μl, 10 equiv.) and tetrakis-(triphenylphosphine)-palladium (14 mg, 0.15 equiv.) were added to the mixture, the reaction was performed under room temperature. The reaction was monitored by LC-MS until D-1 has been completely consumed. Subsequently, the organic solvent was removed under reduced pressure, the crude product was subjected to column chromatography for purification, and the pure product D-2 was obtained.

(58) LC-MS (ESI): [M+H]+: 431

(59) 1H NMR (400 MHz, CDCl.sub.3) δ=7.47 (d, J=12.0 Hz, 1H), 5.42 (d, J=12.0 Hz, 1H), 4.68 (s, 2H), 3.83 (d, J=3.2 Hz, 1H), 3.71 (s, 1H), 3.57 (d, J=2.8 Hz, 1H), 3.39 (d, J=5.39 Hz, 1H), 2.68-2.72 (m, 1H), 2.31-2.35 (m, 1H), 2.18-2.23 (m, 4H), 1.93-2.06 (m, 2H), 1.60 (dd, J=4.8, 12.4 Hz, 1H), 1.20-1.25 (m, 3H), 1.07 (s, 3H), 0.97 (d, J=7.2 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H).

(60) Synthesis of Compound D-3

(61) AS1411 (20 nmol) was dissolved in a buffer of sodium carbonate and sodium bicarbonate (200 μL, pH 9.0) with pH=9.0, both D-2 (5 mg, 1200 nmol) in DMSO (200 μl) and DMT-MM (200 nmol) in ddH.sub.2O (200 μl) were added at the same time to the buffer. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification, and target product D-3 was obtained.

(62) MS: calculated 8896 (found 8895.9).

(63) The spectrums of the corresponding starting materials and products in embodiment 3 are shown in FIGS. 7-12.

(64) Embodiment 4 Preparation of Compound (4)

(65) ##STR00025##

(66) Synthesis of Compound G-2

(67) TP (360 mg, 1 mmol) was dissolved in DMF at a temperature of 0° C. and in the presence of nitrogen gas, Z-1 (680 mg, 2.5 mmol) and silver oxide (458 mg, 2 mmol) were then added. The temperature of the reaction system was naturally increased to room temperature, and the system was maintained at this temperature for 24 hours to facilitate the reaction. When TLC determined that the reaction was complete, water was added, ethyl acetate was used for extraction and then the organic phases were combined together and washed by saturated saline, subsequently dried by anhydrous sodium sulfate, filtered, and condensed. The crude product was thus obtained.

(68) Synthesis of Compound G-3

(69) G-2 (552 mg, 1 mmol) was dissolved in DCM at 0° C., sodium hydroxide aqueous solution (80 mg, 2 mmol) was added. The reaction system was maintained at said temperature for reaction. When TLC determined that the reaction was complete, dichloromethane was applied for extraction and the organic phase was washed by saturated saline, dried by anhydrous sodium sulfate, filtered and subjected to evaporation. G-3 crude product was thus obtained.

(70) Synthesis of Compound G-4

(71) AS1411 (20 nmol) was dissolved in a buffer of sodium carbonate and sodium bicarbonate (200 L, pH 9.0) with pH=9.0, both G-3 (5 mg, 1000 nmol) in DMSO (200 μl) and DMT-MM (200 nmol) in H.sub.2O (200 μl) were added to the buffer at the same time. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification, and target product G-4 was thus obtained.

(72) MS: calculated 8992 (found 8992.6).

(73) Embodiment 5 Preparation of Compound (5)

(74) ##STR00026##

(75) Synthesis of Compound H-2

(76) TP (360 mg, 1 mmol) was dissolved in DMF at 0° C. and in the presence of to room temperature, and the system was remained at this temperature for 24 hours to facilitate the reaction. When TLC determined that the reaction was complete, water was added and ethyl acetate was applied for extraction. The organic phases were combined together, washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and condensed. The crude product was thus obtained.

(77) Synthesis of Compound H-2

(78) H-1 (552 mg, 1 mmol) was dissolved in DCM at 0° C., sodium hydroxide aqueous solution (80 mg, 2 mmol) was then added. The system was maintained at said temperature for reaction. When TLC determined that the reaction was complete, dichloromethane was applied for extraction, the organic phase was washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation. H-2 crude product was then obtained.

(79) Synthesis of Compound H-3

(80) AS1411 (20 nmol) was dissolved in a buffer of sodium carbonate and sodium bicarbonate (200 μL, pH 9.0) with pH=9.0, both H-2 (5 mg, 950 nmol) in DMSO (200 μl) and DMT-MM (200 nmol) in H.sub.2O (200 μl) were added to the buffer at the same time. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification, and target product H-3 was then obtained.

(81) MS: calculated 8918 (found 8919.2).

(82) Embodiment 6 Preparation of Compound (6)

(83) ##STR00027##

(84) Synthesis of Compound K-2

(85) TP (360 mg, 1 mmol) and triethylamine (120 mg, 1.1 mmol) were dissolved in dichloromethane, Z-3 (126 mg, 1.1 mmol) was then added to the mixture. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. When TLC determined that the reaction was complete, the organic solvent was removed under reduced pressure, and the crude product was subjected to a quick silica gel column chromatography so as to obtain a pure product K-2.

(86) Synthesis of Compound K-3

(87) K-2 (475 mg, 1 mmol) was dissolved in DCM at 0° C., sodium hydroxide solution (80 mg, 2 mmol) was added to the mixture. The system was maintained at said temperature for reaction. When TLC determined that the reaction was complete, dichloromethane was used for extraction, the organic phase was washed by saturated saline, dried by anhydrous sodium sulfate, filtered and subjected to evaporation, and then K-3 crude product was obtained.

(88) Synthesis of Compound K-4

(89) K-3 (461 mg, 1 mmol) obtained from the previous step was dissolved in DCM at room temperature, HOBT (148 mg, 1.1 mmol) and EDCI (210 mg, 1.1 mmol) were added to the mixture. After reacting at room temperature for 0.5 hours, AS1411 (20 nmol) was introduced to the mixture, and proceeded with the reaction at said temperature for 3 hours. When TLC or LC-MS determined that the reaction was complete, the compound K-4 was then obtained after purification.

(90) MS: calculated 8929 (found 8929.8).

(91) Embodiment 7 Preparation of Compound (7)

(92) ##STR00028##

(93) Synthesis of Compound L-2

(94) TP (360 mg, 1 mmol) was dissolved in DMF at 0° C. and in the presence of nitrogen gas, Z-4 (442 mg, 2.5 mmol) and silver oxide (458 mg, 2 mmol) were then added. The temperature of the reaction system was naturally increased to room temperature, and the system was maintained at this temperature for 24 hours to facilitate the reaction. When TLC determined that the reaction was complete, water was added, ethyl acetate was applied for extraction and the organic phases were combined together, washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and condensed, and then crude product was obtained.

(95) Synthesis of Compound L-3

(96) L-2 (458 mg, 1 mmol) was dissolved in DCM at 0° C., sodium hydroxide solution (80 mg, 2 mmol) was then added. The system was maintained at said temperature for reaction. When TLC determined that the reaction was complete, dichloromethane was used for extraction, the organic phase was washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation, and then L-3 crude was obtained.

(97) Synthesis of Compound L-4

(98) AS1411 (20 nmol) was dissolved in a buffer of sodium carbonate and sodium bicarbonate (200 μL, pH 9.0) with pH=9.0, both L-3 (5 mg, 1120 nmol) in DMSO (200 μl) and DMT-MM (200 nmol) in H.sub.2O (200 μl) were added to the buffer at the same time. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification, and then target product L-4 was obtained.

(99) MS: calculated 8912 (found 8913.2).

(100) Embodiment 8 Preparation of Compound (8)

(101) ##STR00029##

(102) Synthesis of Compound N-2

(103) TP (360 mg, 1 mmol) and triethylamine (151 mg, 1.5 mmol) were dissolved in dichloromethane at 0° C. and nitrogen, Z-4 (177 mg, 1.1 mmol) was then added. The temperature of the reaction system was increased to room temperature for reacting. When TLC determined that the reaction was complete, the organic solvent was removed under reduced pressure, and crude product was subjected to a quick silica gel column chromatography for purification, and then a pure product N-2 was obtained.

(104) Synthesis of Compound N-3

(105) N-2 (480 mg, 1 mmol) was dissolved in acetonitrile, potassium carbonate (129 mg, 1.2 mmol) was added to the mixture, and subsequently AS1411 (20 nmol) was added under the protection of nitrogen. The temperature of the reaction system was increased to 50° C. to facilitate the reaction for 4 hours. After the TLC or LC-MS determined that the reaction was complete, N-3 was obtained through purification.

(106) MS: calculated 8886 (found 8887.4).

(107) Embodiment 9 Preparation of Compound (9)

(108) ##STR00030##

(109) Synthesis of Compound O-2

(110) TP (360 mg, 1 mmol) and N,N-dimethyl pyridine (146 mg, 1.2 mmol) were dissolved in DMF at 0° C. and in the presence of nitrogen gas, Z-5 (266 mg, 1.1 eq) was then added to the mixture. The temperature of the reaction system was increased to room temperature for reacting. When TLC determined that the reaction was complete, the organic solvent was removed under reduced pressure, and the crude product was subjected to a quick silica gel column chromatography for purification and then a pure product O-2 was obtained.

(111) Synthesis of Compound O-3

(112) O-2 (566 mg, 1 mmol) was dissolved in methanol, 50 mg of 10% Pd/C was added to the solution. After the atmosphere was replaced by hydrogen, the reaction was performed at room temperature. When TLC determined the reaction was complete, a suction filtration was carried out and the organic solvent was evaporated so as to obtain the crude product. Further, a suitable purification method was selected to obtain O-3.

(113) Synthesis of compound O-4: AS1411 (20 nmol) was dissolved in a buffer of sodium carbonate and sodium bicarbonate (200 L, pH 9.0) with pH=9.0, both O-2 (5 mg, 1050 nmol) in DMSO (200 μl) and DMT-MM (200 nmol) in H.sub.2O (200 μl) were added to the buffer at the same time. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification, and then target product O-3 was obtained.

(114) MS: calculated 8946 (found 8947.2).

(115) Embodiment 10 Preparation of Compound (50)

(116) ##STR00031##

(117) Synthesis of Compound E-2

(118) TP (360 mg, 1 mmol) was dissolved in DMF at 0° C. and in the presence of nitrogen gas, benzyl bromide (422 mg, 2.5 mmol) and silver oxide (458 mg, 2 mmol) were added to the solution. The temperature of the reaction system was naturally increased to room temperature, and the system was maintained at this temperature for 24 hours to facilitate the reaction. When TLC determined that the reaction was complete, water was added, and ethyl acetate was used for extraction. The organic phases were combined together, washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and condensed so as to obtain the crude product.

(119) Synthesis of Compound E-3

(120) E-2 (450 mg, 1 mmol) was dissolved in THF, sodium hydroxide solution (120 mg, 3 mmol) was added to the solution. the temperature of the reaction system was increased to 75° C. for reaction. When TLC determined that the reaction was complete, the reaction system was then cooled to room temperature. THF was removed by elevated pressure. Dichloromethane was used to carried out the extraction, the organic phase ass washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation so as to obtain E-3 crude product.

(121) Synthesis of Compound E-4

(122) E-3 (468 mg, 1 mmol) was dissolved in dichloromethane, triethylamine (151 mg, 1.5 mmol) was then added to the solution. Methoxycarbonyl benzenesulfonyl chloride (280 mg, 1.2 mmol) in dichloromethane was slowly added dropwise to the solution at 0° C. After the addition, the temperature of the reaction system was naturally increased to room temperature. The reaction was monitored by TLC, when the reaction was complete, the organic phase was washed by water and saturated saline respectively, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation so as to obtain E-4 crude product.

(123) Synthesis of Compound E-5

(124) E-4 (666 mg, 1 mmol) was dissolved in THF, 50 mg of 10% Pd/C was added to the solution. The atmosphere was replaced by hydrogen. The reaction was carried out under room temperature for 5 hours. The reaction was monitored by TLC. After the reaction was complete, Pd/C was removed by suction filtration, and the next step was directly performed. 1 mmole of the resulting product of the above steps was dissolved in DCM at 0° C., lithium hydroxide (38 mg, 2 mmol) aqueous solution was added. The reaction was maintained to react at said temperature. When TLC determined that the reaction was complete, dichloromethane was used for extraction and the organic phase was washed by saturated saline, dried by anhydrous sodium sulfate, filtered and subjected to evaporation so as to obtain E-5 crude product.

(125) Synthesis of Compound E-6

(126) AS1411 (3 mg) was dissolved in a buffer of sodium carbonate and sodium bicarbonate with pH=9.0, both E-5 (5.4 μmol, 150 eq.) in DMSO (54 μl) and DMT-MM (5.4 μmol, 200 eq.) in ddH.sub.2O (54 μL) were introduced to the buffer at the same time. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification so as to obtain target product E-6.

(127) MS: calculated 9012 (found 9012.4).

(128) Embodiment 11 Preparation of Compound (64)

(129) ##STR00032##

(130) Synthesis of Compound F-2

(131) TP (360 mg, 1 mmol) was dissolved in dichloromethane at 0° C., DIFA (195 mg, 1.5 mmol) was then added to the solution. Tert-butyldimethylsilyl triflate (TBSOTf) (317 mg, 1.2 mmol) diluted by dichloromethane was slowly added dropwise to the solution. The reaction was maintained at said temperature for 0.5 hours and then the temperature of the system was increased to room temperature for further reaction for 4 hours. After TLC determined that the reaction was complete, the reaction solution was introduced to a saturated sodium bicarbonate, extracted the mixture with dichloromethane, the resulting product was washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation so as to obtain F-2 crude product.

(132) Synthesis of Compound F-3

(133) F-2 (474 mg, 1 mmol) was dissolved in tetrahydrofuran, an slightly excess amount of LDA was slowly added to the solution at −78° C. under the protection of nitrogen gas. The reaction was maintained at said temperature for 1 hour. Succinic anhydride (100 mg, 1 mmol) was added and then the temperature of the reaction system was naturally increased to room temperature to react for 2 hours. After TLC determined that the reaction was complete, a saturated ammonium chloride solution was added, then, the resulting solution was condensed to remove tetrahydrofuran through evaporation. Dichloromethane was applied for extraction, the resulting compound was washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation so as to obtain F-3 crude product.

(134) Synthesis of Compound F-4

(135) F-3 (574 mg, 1 mmol) was dissolved in a mixture solution of anhydrous tetrahydrofuran and water, tetrabutylammonium fluoride (313 mg, 1.2 mmol) was added to the mixture under room temperature. After stirring the mixture under room temperature for 3 hours, is the resulting solution was condensed and extracted with dichloromethane, washed by saturated saline, dried by anhydrous sodium sulfate, filtered, and subjected to evaporation so as to obtain F-4 crude product.

(136) Synthesis of Compound F-5

(137) F-4 (460 mg, 1 mmol) obtained from the previous steps was dissolved in dichloromethane under room temperature, then HATU (148 mg, 1.1 mmol) and DIEA (210 mg, 1.1 mmol) were introduced to the mixture. The reaction was performed under room temperature for 0.5 hours, AS1411 (20 nmol) was introduced and the reaction was maintained at said temperature for 3 hours. After TLC or LC-MS determined that the reaction was complete, the F-5 compound was then obtained.

(138) MS: calculated 8926 (found 8927.2).

(139) Embodiment 12 Preparation of Compound (22)

(140) ##STR00033##

(141) C-1 (0.91 g, 13 mmol) was dissolved in DMF, sodium bicarbonate (2.18 g, 26 mmol) was added to the solution. After stirring the mixture under room temperature for 1 hour, allyl bromide (2.28 g, 16.9 mmol) was added. The reaction was maintained under room temperature for overnight reaction. After TLC determined that the reaction was complete, EA was added to the reaction system. Water was used to perform extraction for several times, and finally the organic phase was dried by anhydrous sodium sulfate, filtered, and subjected to evaporation so as to obtain C-2 crude product.

(142) Synthesis of Compound W-1

(143) TP (50 mg, 139 μmol) and C-2 (23 mg, 208 μmol) were dissolved in acetonitrile, then NMM (15 μl, 0.5 eq.) was added. The reaction system was maintained under room temperature for 12 hours to facilitate the reaction. After TLC determined that the reaction was complete, the organic solvent was removed under reduced pressure, and the crude product was subjected to a quick silica gel column chromatography for purification so as to obtain a pure product W-1.

(144) LC-MS (ESI): [M+H]+: 471; [M+Na]+: 493

(145) 1HNMR (400 MHz, CDCl3) δ=7.41 (d, J=12.4 Hz, 1H), 5.91-5.98 (m, 1H), 5.47 (d, J=12.4 Hz, 1H), 5.31 (dd, J=1.2, 17.4 Hz, 1H), 5.22 (dd, J=1.2, 10.4 Hz, 1H), 4.68 (s, 2H), 4.61 (d, J=3.6 Hz, 2H), 3.82 (d, J=3.2 Hz, 1H), 3.69 (s, 1H), 3.60 (d, J=2.8 Hz, 1H), 3.38 (d, J=5.6 Hz, 1H), 2.70 (m, 1H), 2.30 (m, 1H), 2.16-2.22 (m, 1H), 1.92-2.06 (m, 2H), 1.57-1.61 (m, 3H), 1.17-1.25 (m, 3H), 1.07 (s, 3H), 0.97 (d, J=7.2 Hz, 3H), 0.87 (d, J=6.8 Hz, 3H).

(146) Synthesis of Compound W-2

(147) W-1 (15 μl, 0.5 eq.) was dissolved in tetrahydrofuran, morpholine (50 μl, 10 equiv.) and tetrakis(triphenylphosphine)-palladium (14 mg, 0.15 equiv.) were added to the solution. The reaction was carried out under room temperature. The reaction was monitored by LC-MS until all W-1 had been completely consumed. After the removal of the organic solvent under reduced pressure, the crude product was subjected to column chromatography for purification so as to obtain the pure product W-2.

(148) LC-MS (ESI): [M+H]+: 431

(149) 1H NMR (400 MHz, CDCl3) δ=7.47 (d, J=12.0 Hz, 1H), 5.42 (d, J=12.0 Hz, 1H), 4.68 (s, 2H), 3.83 (d, J=3.2 Hz, 1H), 3.71 (s, 1H), 3.57 (d, J=2.8 Hz, 1H), 3.39 (d, J=5.39 Hz, 1H), 2.68-2.72 (m, 1H), 2.31-2.35 (m, 1H), 2.18-2.23 (m, 4H), 1.93-2.06 (m, 2H), 1.60 (dd, J=4.8, 12.4 Hz, 1H), 1.20-1.25 (m, 3H), 1.07 (s, 3H), 0.97 (d, J=7.2 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H).

(150) Synthesis of Compound W-3

(151) Sgc8c (20 nmol) was dissolved in a buffer of sodium carbonate and sodium bicarbonate (200 μL, pH 9.0) with pH=9.0, both D-2 (5 mg, 1200 nmol) in DMSO (200 μl) and DMT-MM (200 nmol) in H.sub.2O (200 μl) were added to the buffer at the same time. The reaction system was maintained at room temperature for 12 hours to facilitate the reaction. After the reaction was complete, the crude product was subjected to RP HPLC for purification so as to obtain target product W-3.

(152) MS: calculated 13263 (found 13261.9).

(153) The spectrums of the corresponding starting materials and products in embodiment 12 are shown in FIGS. 2, 13-17.

EXAMPLE 1

Inhibition of Triptolide-AS1411 Conjugate on the Growth of Cancer Cells In Vitro

(154) 1. Experimental Materials:

(155) Chemicals:

(156) Triptolide (TP), source: commercially available;

(157) AS1411 (also named as “nucleolin aptamer”), source: commercially available;

(158) Triptolide-AS1411 conjugate (also named as “chemical 1”), source: compound (3) prepared in Embodiment 3.

(159) Cell culture medium (DMEM, McCoy's, RPMI-1640, Leibovitz'sL-05) was purchased from GIBCO, and fetal bovine serum was purchased from Hyclone.

(160) CCK-8 used for detecting cell activities was purchased from Sigma.

(161) 5 pancreatic cancer cell lines (MiaPaCa-2, PANC-1, BxPC-3, SW1990 and ASPC-1) used in the experiments were all purchased from Shanghai Cell Bank.

(162) 2. Experimental Methods:

(163) 1) Cell Culture:

(164) The culture medium of MiaPaCa-2 and PANC-1 was DMEM, the culture medium of BxPC-3 and ASPC-1 was RPMI-1640, and the culture medium of SW1990 was L-05. Fetal bovine serum and two antibiotics were added into the above media so as to form a final culture medium with a final content of 10% and 1%. Cells were incubated in an incubator at 37° C. and with 5% CO.sub.2.

(165) 2) Study on Anti-Cancer Activity:

(166) Pancreatic cancer cells (MiaPaCa-2, PANC-1, BxPC-3, SW1990 and ASPC-1) were uniformly seeded into a 96-well plate with a low density (1×10.sup.3˜1×10.sup.4, depending on the specific cell lines, and the conditions were referred to Shanghai Cell Bank). After placed in incubator for adhering overnight, the used medium was replaced by a serum free medium containing drug. Triptolide was dissolved in DMSO to prepare a stock solution with 10 nM, the triptolide-nucleolin aptamer conjugate and the nucleolin aptamer were both dissolved in the serum free medium containing drug so as to form a solution with 10 mM, and these solutions were used right after preparation. The serum free medium containing drug was used as the blank reference, the concentration gradient of triptolide, triptolide-nucleolin aptamer conjugate and nucleolin aptamer used in treatments were: 0, 25, 50, 100 and 200 nM. The cells were then incubated in the incubator at 37° C. and with 5% CO.sub.2. Cell activities were measured by MTT. The operation was performed for 4 times.

(167) 3. Experimental Results:

(168) As compared with blank references, TP and TP-AS1411 conjugate can significantly inhibit the proliferation of pancreatic cancer cells in a time and dose dependent manner in the concentration range of 50 nM-200 nM. Nucleolin aptamers do not have significant affect on pancreatic cancer cells. As compared to nucleolin aptamers, TP-nucleolin aptamer conjugate has significant effect on pancreatic cancer cells. Please refer to Table 1, FIGS. 18-19 and 29 for the details of the results.

(169) TABLE-US-00004 TABLE 1 Dose concentration (nM) Nucleolin aptamers Triptolide Chemical 1 Absorbance (24 h) 0 0.880 0.872 0.872 0.861 0.870 0.871 0.862 0.851 0.885 0.876 0.852 0.868 25 0.873 0.852 0.876 0.849 0.745 0.764 0.718 0.690 0.722 0.725 0.701 0.704 50 0.856 0.852 0.859 0.832 0.436 0.430 0.454 0.424 0.444 0.458 0.449 0.432 100 0.847 0.861 0.838 0.849 0.393 0.397 0.403 0.364 0.373 0.373 0.381 0.372 200 0.838 0.834 0.832 0.815 0.365 0.366 0.402 0.399 0.371 0.385 0.363 0.373 Absorbance (48 h) 0 0.881 0.873 0.882 0.863 0.872 0.871 0.864 0.853 0.882 0.869 0.854 0.860 25 0.874 0.870 0.886 0.860 0.296 0.322 0.317 0.322 0.326 0.312 0.322 0.281 50 0.865 0.862 0.869 0.851 0.219 0.223 0.231 0.220 0.195 0.196 0.211 0.196 100 0.857 0.853 0.860 0.834 0.211 0.206 0.223 0.212 0.204 0.205 0.220 0.231 200 0.848 0.844 0.842 0.834 0.200 0.218 0.222 0.213 0.193 0.208 0.193 0.197

EXAMPLE 2

Inhibition of Triptolide-SGC8C Conjugate on the Growth of Cancer Cells In Vitro

(170) 1. Experimental Materials:

(171) Chemicals:

(172) Triptolide (TP), source: commercially available;

(173) SGC8C (also named as “leukemia aptamer”), source: commercially available;

(174) Triptolide-SGC8C conjugate (also named as “chemical 2”), source: compound (22) prepared in Embodiment 12.

(175) Cell lines: acute lymphoblastic leukemia T-cells (CCRF-CEM) and hepatocyte (L-02).

(176) 2. Experimental Methods:

(177) The culture medium of acute lymphoblastic leukemia T-cells (CCRF-CEM) and hepatocyte (L-02) was RPMI-1640. Fetal bovine serum and two antibiotics were added into the above media so as to form a final culture medium with a final content of 10% and 1%. Cells were incubated in an incubator at 37° C. and with 5% CO.sub.2. Growth conditions of the cells were constantly observed and cell counting was performed, and all the experiments were carried out on cells in logarithmic growth phase.

(178) Preparation of drugs: triptolide was dissolved in DMSO for preparing a stock solution with 1 mg/ml and was stored in a refrigerator at −20° C.; sgc8c was dissolved in the serum free medium containing drug, and stored in the refrigerator at −20° C. after sgc8c fully dissolved; triptolide-sgc8c conjugate was fully dissolved in double-distilled water and it was used right after the preparation.

(179) Study on anti-cancer activity: acute lymphoblastic leukemia T-cells (CCRF-CEM) and liver cells (L-02) were uniformly seeded into a 96-well plate in a low density (1×10.sup.3˜1×10.sup.4, depending on the specific cell lines) and were placed in an incubator overnight for adhering, the used medium was replaced by a serum free medium containing drug. Triptolide was dissolved in DMSO for preparing a stock solution with 10 nM, the triptolide-sgc8c conjugate was dissolved in the serum free medium containing drug so as to form a solution with 10 mM, and it was used right after the preparation. The serum free medium containing drug was used as the blank reference, the concentration gradient of triptolide and triptolide-sgc8c conjugate used in the treatments: 0, 25, 50, 100 and 200 nM. The cells were then cultured in the incubator at 37° C. and with 5% CO.sub.2. Cell activities were measured by MTT. The operations were repeated for 3 times.

(180) 3. Experimental Results:

(181) As compared with the blank references, TP exhibits significant cytotoxicity to CCRF-CEM and L-02 cells in the concentration range of 50 nM to 200 nM in a dose dependent manner. TP-sgc8c conjugate showed significant cytotoxicity to CCRF-CEM cells but no significant effects to L-02 cells. As compared to blank references, sgc8c did not show significant cytotoxicity on both of the cells. Please refer to Table 2, FIGS. 20 and 21 for the details of the results.

(182) TABLE-US-00005 TABLE 2 Dose concentration (nM) Leukemia aptamer TP Chemical 2 Absorbance (CCRF-CEM) 0 0.80192 0.82148 0.88475 0.80192 0.82148 0.88475 0.89837 0.84378 0.86153 25 0.82546 0.82818 0.82498 0.75546 0.75818 0.75498 0.77313 0.79694 0.77319 50 0.81192 0.81148 0.81475 0.55019 0.54412 0.54474 0.54661 0.55778 0.57231 100 0.80476 0.80173 0.81221 0.26076 0.27173 0.28021 0.28186 0.29851 0.29817 200 0.80123 0.80604 0.80617 0.19023 0.18004 0.19017 0.18421 0.18219 0.19244 Absorbance (L-02) 0 0.88955 0.89123 0.88297 0.90192 0.92148 0.98475 0.89715 0.87213 0.86511 25 0.88192 0.88148 0.88475 0.75546 0.75818 0.75498 0.86596 0.86697 0.88065 50 0.88019 0.88412 0.87474 0.59019 0.59412 0.59474 0.84059 0.87819 0.84312 100 0.88476 0.87173 0.86221 0.29076 0.27173 0.28021 0.85123 0.85604 0.84617 200 0.8754 0.87718 0.85498 0.23023 0.23004 0.23017 0.85751 0.84533 0.84191

EXAMPLE 3

Biodistribution of Triptolide-AS1411 Conjugate In Vivo

(183) 1. Experimental Materials:

(184) Chemicals and reagents: triptolide (TP), source: commercially available;

(185) AS1411 (also named as “nucleolin aptamer”), source: commercially available;

(186) Triptolide-nucleolin aptamer conjugate, source: compound (3) prepared in Embodiment 3.

(187) RPMI-1640 medium, fetal bovine serum, penicillin-streptomycin, matrigel, anhydrous ethanol, saline, ethyl acetate, acetonitrile and so forth.

(188) Cell: human pancreatic cancer cell line BxPC-3.

(189) Experimental animals: female nude mice.

(190) Experimental Instrument: ultraclean benches, CO.sub.2 incubator, inverted microscope, high speed centrifuges, ultra high speed centrifuge, vacuum drier and high performance liquid chromatography system.

(191) 2. Experimental Methods:

(192) 2.1 Establishment of Pancreatic Cancer Model

(193) 2.1.1 Culture of BxPC-3 cell lines: human pancreatic cancer cell line BxPC-3 was purchased from Chinese Academy of Science Shanghai Cell Bank. The cells were cultured in RPMI 1640 medium (purchased from sigma) containing 10% of fetal bovine serum (purchased from sigma) and 1.2 ml/1000 ml of penicillin-streptomycin (purchased from sigma) and were incubated in an incubator at 37° C. and with 5% CO.sub.2. The inverted microscope was used for observation and cell counting, and all the experiments were carried out on cells in logarithmic growth phase.

(194) 2.1.2 Establishment of xenograft tumor-bearing mice with human pancreatic cancer cell line BxPC-3: female nude mice were provided and maintained in animal house in School of Chinese Medicine, Hong Kong Baptist University. BxPC-3 cells in logarithmic growth phase were used. 50:50 matrigel and serum free medium were resuspended to 2×10.sup.7/ml. Female nude mice (20 g, 6-8 weeks) were inoculated with 100 μl cell suspension through subcutaneous injection at the right side of the back. The size of the tumors were measured by a bidirectional vemier caliper every day, and the formula for calculating the cancer size is: V=(length+width 2)/2, the length was the longest diameter of the cancer, and the width was the shortest diameter perpendicular to the length, and the following experiments were performed when the tumor reached the size of 200 mm.sup.3.

(195) 2.2 Grouping of tested animals and treatments

(196) 2.2.1 Preparation of the drugs: triptolide and triptolide-nucleolin aptamer conjugate. Triptolide was dissolved in a 50:50 ethanol/physiological saline solution for forming a drug solution with 0.6 mg/ml and was stored in a 4° C. refrigerator for further use; triptolide-nucleolin aptamer conjugate was measured and dissolved in a 50:50 ethanol/physiological saline solution for forming a drug solution with 22.0 mg/ml and was stored in 4° C. refrigerator for further use.

(197) 2.2.2 Grouping and treatments: when the tumor reached the size of 200 mm.sup.3, 30 tumor-bearing mice were randomly divided into A and B groups. In group A, 0.6 mg/kg of triptolide in ethanol/physiological saline solution was given through tail vein injection; in group B, 22.0 mg/kg of triptolide-nucleolin aptamer conjugate in ethanol/physiological saline solution was given through tail vein injection with the dosage 1 ml/kg. At 0.5, 2, 6, 12 and 24 hours, three mice in each groups were anesthetized by intraperitoneal injection with pentobarbital sodium, blood was collected through heart puncture, tissues such as heart, liver, spleen, lung, kidney and tumor tissue were removed and collected. The blood was centrifuged under 4° C. and 3000 rpm for 20 minutes, and serum was then obtained for further application; tissues such as heart, liver, spleen, lung, kidney and tumor tissues were stored at −80° C. for further application.

(198) 2.3 Detection of the Content of Triptolide/Triptolide-Nucleolin Aptamer Conjugate in Tissues by HPLC

(199) Tissues (heart, liver, spleen, lung, kidney and cancer tissue) with a certain weight were measured and a certain amount of pH 7.5 PBS solution was added to the tissues to perform homogenization. 0.2 ml of homogenized mixture was transferred to an eppendorf tube, 1.2 ml of ethyl acetate was vortex extracted for 3 minutes and centrifuged under 8000 rpm for 5 minutes. The upper layer of organic solution (1 ml) was transferred to another eppendorf tube for vacuum drying, and the residue was dissolved in 0.1 ml ethanol and was centrifuged under 4° C. and 20000 rpm for 10 minutes. The supernatant (10 μl) was injected to Agilent 1100 HPLC. The chromatography conditions were: separation column Symmetry Shield™ RP18 column (4.6 mm×250 mm, 5 um), the protective column ODS guid column (3.9 mm×20 mm, 5 um), the mobile phase: acetonitrile-water (23:77); the flow rate: 1.0 mL/min; the temperature of the column: 35° C.; the detection wavelength: 219 nm; the injection volume: 20.0 μL.

(200) 2.4 In Vivo Stability of Triptolide-Nucleolin Aptamer Conjugate

(201) B samples in 2.2.2 were used. The concentration of free triptolide and triptolide-nucleolin aptamer conjugate in the tissues at different time interval was measured by the HPLC using the method set up in 2.3 and the release percentage was calculated. The formula: release percentage=(the concentration of triptolide)/(the concentration of triptolide+the concentration of triptolide-nucleolin aptamer), and the stability of the drug in the tissues were examined quantitatively.

(202) 2.5 Distribution of Triptolide-Nucleolin Aptamer Conjugate within Tissues

(203) Samples A and B in 2.2.2 were used. The distribution of the drug in normal tissues and cancer tissues were measured and determined by the HPLC using the method set up in 2.3.

(204) 2.6 Statistic analysis

(205) The data are represented by mean±standard deviation (SD), and the data were treated by Graphpad Prism 6.0 statistic software. Statistical significance was determined by t test and analysis of variance.

(206) 3. Experimental Results:

(207) 1. In vivo biodistribution of triptolide-nucleolin aptamer conjugate: the degree of dissociation of triptolide-nucleolin aptamer conjugate in different tissues at different time was measured by HPLC. The results are as follows. After 24 hours, only few triptolide-nucleolin aptamer conjugate was dissociated or not dissociated in normal tissues such as plasma, heart, liver, spleen, lung, kidney and so forth; triptolide-nucleolin aptamer conjugate was greatly dissociated in tumor tissue, and the degree of dissociation increases with time. The above results prove that the acid sensitive-vinylether bond used for connecting triptolide and nucleolin aptamer also exerts effect in vivo. The bond of the conjugate does not break in normal tissues, C.sub.14 group is protected and the toxicity is reduced; the bond of the conjugate breaks in tumor tissue to release TP so as to achieve therapeutic effects, see Table 3 and FIG. 22.

(208) TABLE-US-00006 TABLE 3 TP release percentage (%) in tissue with time 0.5 h 2 h 6 h 12 h 24 h Plasma 1.8 5.3 14.3 19.1 23.1 2.0 5.9 15.0 20.3 23.8 2.3 6.4 15.7 20.9 24.0 Heart 0.6 2.8 7.6 13.1 17.3 1.0 3.2 7.9 14.0 18.2 0.8 3.1 7.8 13.6 17.5 Liver 3.5 8.5 16.4 24.5 32.6 3.4 8.2 15.0 23.1 30.1 3.8 9.0 17.3 26.2 34.5 Spleen 1.3 4.5 10.3 14.9 16.2 1.7 4.9 11.2 15.6 16.8 2.1 5.2 12.4 16.1 17.3 Lung 1.4 3.8 7.9 11.2 14.2 0.9 3.1 7.2 10.3 13.4 1.1 2.6 6.8 10.1 13.1 Kidney 5.4 10.2 18.9 11.2 2.3 5.1 9.6 17.8 10.3 1.9 6.1 10.9 19.9 11.7 3.0 Tumor 23.6 39.1 49.2 60.6 78.6 25.8 40.9 50.7 62.3 80.1 26.3 41.0 52.1 64.1 81.2

(209) 2. Selective biodistribution of triptolide-nucleolin aptamer conjugate in vivo: the biodistribution of the drug in normal organs and tumor tissues were measured by HPLC. The results are as shown in FIG. 22. 0.5 hour after administration, the drug concentrations in blood of experiment group A and the control group B rapidly increase to a maximum, however, the elimination rate of the drug in the experiment group A is slower than that of the control group B (FIG. 23). Comparing the experiment group A with the negative control group B, the distribution tendency of the drug in heart, spleen and lung are similar throughout the experimental period (all are converted to the concentration of triptolide). 0.5-2 hours after administration, triptolide was rapidly distributed to heart, spleen and lung issues, and it started to decrease 4 hours after administration (FIGS. 24-26). On the other hand, comparing the experiment group A with the negative control group B, the distribution tendency of the drug in liver, kidney and cancer are quite different throughout the experimental period (all are converted to the concentration of triptolide). In the experiment group A, the triptolide concentration in liver, kidney tissues was significantly lower than that in the control group B, and the triptolide concentration in tumor tissues was significantly higher than that in control group B (FIGS. 27-29). The above results indicate that the modifications of nucleolin aptamer can enhance the selectivity of triptolide to direct and accumulate at the cancer tissues so as to avoid accumulation in other tissues, especially in liver and kidney tissues. Please refer to Table 4 and FIGS. 23-29 for results of the experiment.

(210) TABLE-US-00007 TABLE 4 Group A TP Group B TP concentration concentration (ng/ml) (ng/ml) Plasma 0.5 h  87.3 84.5 82.7 85.8 83.9 81.3  2 h 76.7 78.4 73.2 38.8 43.9 44.3  6 h 47.5 45.7 43.1 17.8 23.3 21.4 12 h 20.1 13.9 26.2 10.7 19.8 6.3 24 h 1.4 1.7 3.8 3.1 6.9 1.7 Heart 0.5 h  0 0 0 3.2 2.1 2.4  2 h 1.5 1.2 1.1 1.7 1.4 1.1  6 h 0.5 0.3 0.2 1.9 2.7 1.1 12 h 0 0 0 0.6 0.2 0 24 h 0 0 0 0 0 0 Lung 0.5 h  2.3 0.9 1.6 2.1 1.6 1.8  2 h 1.9 1.3 1.4 2.0 1.6 1.3  6 h 0.7 0.4 0.5 1.2 0.8 0.9 12 h 1.3 0.1 0.2 1.4 0 0.1 24 h 0 0 0 0 0 0 Spleen 0.5 h  2.7 0.9 4.4 2.9 3.3 3.4  2 h 8.7 7.3 9.6 11.7 9.7 9.3  6 h 9.8 6.7 4.2 4.3 7.3 6.1 12 h 0.5 2.1 0.7 0.1 0.3 2.6 24 h 0 0 1.6 0.7 0.3 2.8 Liver 0.5 h  22.6 12.3 6.9 69.3 58.2 54.4  2 h 4.3 7.9 15.2 74.9 57.4 64.8  6 h 10.2 5.7 2.4 68.3 37.9 60.7 12 h 43.4 1.3 6.5 38.7 35.2 40.7 24 h 0 0 0 28.9 15.3 16.4 Kidney 0.5 h  18.7 13.9 24.3 52.7 65.3 44.8  2 h 16.4 12.1 20.7 49.8 53.5 46.2  6 h 9.3 16.4 4.2 34.5 28.8 32.3 12 h 11.3 2.7 5.9 14.4 4.7 8.9 24 h 7.5 8.4 7.1 0.9 6.7 1.3 Tumor 0.5 h  9.6 10.5 8.3 0.5 0.7 0.33  2 h 9.8 11.4 9.6 1.7 1.3 1.1  6 h 8.3 9.5 8.7 1.5 1.2 1.4 12 h 5.4 7.2 6.3 0 0 0 24 h 3.3 2.4 3.9 0 0 0

(211) In the novel anticancer compound, novel triptolide derivatives and the preparation thereof of the present invention, nucleic acid aptamers and triptolide are used as starting materials, special bonds are introduced through hydroxyl at C.sub.14, epoxy and five-membered lactone ring of the triptolide so as to connect to the nucleic acid aptamer. The triptolide derivatives obtained by the modification have good performance in targeting, have strong anti-cancer activity, low toxicity and side effects, good water solubility and bioavailability. The techniques involved in the invention are scientific and rational, the quality is controllable; the preparation process is reproducible and suitable for production.